Morphine

BreastfeedingPediatric
  • TRADE NAMES: Anamorph; Astramorph; Avinza (Ligand); Contalgin; Duramorph (Baxter, Elkins-Sinn); Epimorph; Infumorph (Baxter); Kadian (aaiPharma); Morphabond (Inspirion); Morphine-HP; MOS; Moscontin; MS Contin (Purdue); MS-IR; MS/S; MSIR Oral (Purdue); MST Continus; OMS Oral; Oramorph SR; RMS; Roxanol (aaiPharma); Sevredol; Statex
  • INDICATIONS: Severe pain, acute myocardial infarction
  • CLASS: Opiate agonist
  • HALF-LIFE: 2–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Buprenorphine, Cimetidine, Furazolidone, MAO inhibitors, Metformin, Mianserin, Pentazocine, Rifapentine, Trospium

PREGNANCY CATEGORY: C

ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and INTERACTION WITH ALCOHOL

See full prescribing information for complete boxed warning.

Our database has 70 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top